Recurrent oncogenic translocations involving Ig or TCR loci characterize human lymphoid malignancies. These translocations often derived from mis-repaired DNA double stand breaks (DSBs) generated during normal lymphocyte development. Availability of free DNA end, proper end-processing and the mis-joining of distal DNA ends form the three essential steps for chromosomal translocations. Developmental DSBs in lymphocytes are normally repaired by the non-homologous end-joining (NHEJ) pathway with help from the alternative-end joining (A-EJ) pathway(s) that preferentially use micro-homology (MH) at the junctions. NHEJ is also responsible for end-processing, such as opening the hairpin ends at Ig/ TCR loci generated during V(D) recombination. Sequence analyses revealed that NHEJ and A-EJ also mediate the mis-repairs that generate translocations. Thus understanding the mechanism and regulation of NHEJ and A-EJ have broad implications in lymphomagenesis. DNA-PKcs is the catalytic subunit of the DNA-dependent protein-kinase (DNA-PK), a NHEJ factor and a PI3K related protein kinase. In the absence of DNA-PKcs, direct end-ligation is largely normal, but hairpin opening-a form of end-processing required for sealed hairpin ends before ligation, is completely blocked. Here we report that in a knockin mouse model expressing the kinase-dead (KD) form of DNA-PKcs alone (DNA-PKcsKD/KD), direct end-ligation is completely blocked, leading to embryonic lethality similar to core NHEJ deficient (e.g.Lig4-/- ) mice. Co-deletion of Ku70 that is necessary for the recruitment of DNA-PKcs to DNA, rescues the embryonic development of DNA-PKcsKD/KD mice, indicating that DNA-PKcs protein regulates end-ligation at DNA ends. Despite end-ligation defects, DNA-PKcsKD/KD cells open hairpin normally, but only in the presence of normal ATM kinase activity, revealing a previous unrecognized role of ATM in hairpin opening. Finally in contrast to frequent A-EJ mediated IgH-Myc translocations and aggressive lymphomas in other NHEJ/p53 double deficient mice, lymphomas are rare in DNA-PKcsKD/KDp53-/- mice despite the severe genomic instability, indicating potentially defects in A-EJ. DNA-PKcs is auto-phosphorylated and phosphorylated by ATM upon DSBs. Based on these findings, we hypothesize that DNA-PKcs phosphorylation regulates hairpin opening (Aim1), end-ligation (Aim 2) and A-EJ (Aim3) to suppress lymphomagenesis.
Aim1 will address how redundant phosphorylation of DNA-PKcs and Artemis by ATM and DNA-PKcs promotes hairpin opening.
Aim 2 proposes to test the hypothesis that autophosphorylation of DNA- PKcs at the DNA ends is necessary for ends-ligation by identifying functional relevant autophosphorylation sites on DNA-PKcs.
Aim 3 will test the hypotheses that DNA-PKcs KD protein physically blocks end-resection and suppress A-EJ and oncogenic translocation by characterizing class switch recombination (mediated by A- EJ and NHEJ) and IgH-myc oncogenic translocations in DNA-PKcsKD/KD cells and mice. Together these studies will determine the role of DNA-PKcs phosphorylation in DNA repair and translocations. In the future, DNA- PKcs phosphorylation will provide an attractive target to regulate NHEJ and A-EJ for cancer treatments.

Public Health Relevance

Our proposed study addresses 1) how phosphorylation of DNA-PKcs and Artemis regulates hairpin opening during NHEJ 2) how auto-phosphorylation of DNA-PKcs regulates end-ligation during NHEJ and 3) how DNA-PKcs regulates A-EJ during immunoglobulin class switch recombination and oncogenic translocations. The overall goal of the study is to elucidate the function and regulation of DNA-PKcs structure through phosphorylation and its implications on chromosomal translocations and lymphomagenesis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA184187-05
Application #
9613791
Study Section
Cancer Etiology Study Section (CE)
Program Officer
Witkin, Keren L
Project Start
2014-12-01
Project End
2019-11-30
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pediatrics
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Hung, Putzer J; Johnson, Britney; Chen, Bo-Ruei et al. (2018) MRI Is a DNA Damage Response Adaptor during Classical Non-homologous End Joining. Mol Cell 71:332-342.e8
Crowe, Jennifer L; Shao, Zhengping; Wang, Xiaobin S et al. (2018) Kinase-dependent structural role of DNA-PKcs during immunoglobulin class switch recombination. Proc Natl Acad Sci U S A 115:8615-8620
Liu, Xiangyu; Shao, Zhengping; Jiang, Wenxia et al. (2017) PAXX promotes KU accumulation at DNA breaks and is essential for end-joining in XLF-deficient mice. Nat Commun 8:13816
Zhou, Yi; Lee, Ji-Hoon; Jiang, Wenxia et al. (2017) Regulation of the DNA Damage Response by DNA-PKcs Inhibitory Phosphorylation of ATM. Mol Cell 65:91-104
Yamamoto, Kenta; Wang, Jiguang; Sprinzen, Lisa et al. (2016) Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors. Elife 5:
Jiang, Wenxia; Lee, Brian J; Li, Chen et al. (2015) Aberrant TCR? rearrangement underlies the T-cell lymphocytopenia and t(12;14) translocation associated with ATM deficiency. Blood 125:2665-8
Jiang, Wenxia; Crowe, Jennifer L; Liu, Xiangyu et al. (2015) Differential phosphorylation of DNA-PKcs regulates the interplay between end-processing and end-ligation during nonhomologous end-joining. Mol Cell 58:172-85
Pinkney, Kerice A; Jiang, Wenxia; Lee, Brian J et al. (2015) Haploinsufficiency of Bcl11b suppresses the progression of ATM-deficient T cell lymphomas. J Hematol Oncol 8:94
Xing, Mengtan; Yang, Mingrui; Huo, Wei et al. (2015) Interactome analysis identifies a new paralogue of XRCC4 in non-homologous end joining DNA repair pathway. Nat Commun 6:6233
Yamamoto, K; Lee, B J; Li, C et al. (2015) Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia 29:1414-24